Anthem BioSciences Ltd (ANTH)

Currency in INR
915.00
+1.45(+0.16%)
Closed·
ANTHEM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
899.10922.00
52 wk Range
579.15977.55
Key Statistics
Bid/Ask
914.10 / 915.00
Prev. Close
913.55
Open
909.95
Day's Range
899.1-922
52 wk Range
579.15-977.55
Volume
502.81K
Average Volume (3m)
678.23K
1-Year Change
31.3523%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANTHEM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
920.13
Upside
+0.56%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Anthem BioSciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 920.13
(+0.56% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy1,000.00+9.29%900.00MaintainNov 05, 2026
Jefferies
Buy1,050.00+14.75%-New CoverageAug 20, 2026
JPMorgan
Buy900.00-1.64%850.00MaintainJul 23, 2026
Nomura/Instinet
Buy900.00-1.64%740.00MaintainMay 22, 2026
JPMorgan
Buy850.00-7.10%790.00MaintainMay 21, 2026

Anthem BioSciences Ltd Earnings Call Summary for Q2/2027

  • Q2 revenue rose 8% sequentially to INR 594 crore; EBITDA margin expanded to 50.6%, up from 43% in FY 2026, driven by cost discipline.
  • One late-stage molecule commercialized, bringing total to 15; five molecules launched in 18 months with $10B+ aggregate market potential.
  • Management expects double-digit growth long-term; Unit 4 Phase 1 capex at INR 1,200 crore, commissioning planned for March 2028.
  • Company shifting to 'solution provider' for complex molecules; reduced China sourcing to 20-21%, up domestic procurement to 75-78%.
  • Stock up 2.64% to $877 but down 50% over six months; analyst consensus at Hold amid customer concentration risk and new-tech monetization uncertainty.
Last Updated: 2026-11-04, 03:10 a/m
Read Full Transcript

Earnings

Latest Release
Sep 02, 2026
EPS / Forecast
2.10 / 1.50
Revenue / Forecast
4.18B / 4.19B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.92
Dividend Yield
0.22%
Industry Median 0.66%
Annualized payout
2.00
Paid annually
5-Years Growth
-
Growth Streak

ANTHEM Income Statement

Compare ANTHEM to Peers and Sector

Metrics to compare
ANTHEM
Peers
Sector
Relationship
P/E Ratio
83.8x44.3x−0.2x
PEG Ratio
4.800.710.00
Price/Book
15.7x4.1x2.6x
Price / LTM Sales
24.9x6.8x2.8x
Upside (Analyst Target)
0.9%16.8%62.1%
Fair Value Upside
Unlock3.6%9.5%Unlock

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Employees
2282
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
72.19M12.82%64.12B
Other Institutional Investors
57.46M10.20%51.04B
Public Companies & Retail Investors
433.55M76.98%385.12B
Total
563.19M100.00%500.29B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Viridity Tone Llp3.78%21,313,79518,933,044
Portsmouth Technologies LLC2.73%15,396,32713,676,557

People Also Watch

727.00
LENS
+1.20%
397.00
ACMO
-2.67%
162.48
PINL
+0.53%
1,658.60
RUBI
-4.71%

FAQ

What Is the Anthem BioSciences (ANTHEM) Stock Price Today?

The Anthem BioSciences stock price today is 915.00 INR.

What Stock Exchange Does Anthem BioSciences Trade On?

Anthem BioSciences is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Anthem BioSciences?

The stock symbol for Anthem BioSciences is "ANTHEM."

Does Anthem BioSciences Pay Dividends? What’s The Current Dividend Yield?

The Anthem BioSciences dividend yield is 0.2%%.

What Is the Anthem BioSciences Market Cap?

As of today, Anthem BioSciences market cap is 514.51B INR.

What Is Anthem BioSciences's Earnings Per Share (TTM)?

The Anthem BioSciences EPS (TTM) is 10.92.

When Is the Next Anthem BioSciences Earnings Date?

Anthem BioSciences will release its next earnings report on Dec 02, 2026.

From a Technical Analysis Perspective, Is ANTHEM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Anthem BioSciences Stock Split?

Anthem BioSciences has split 0 times.

How Many Employees Does Anthem BioSciences Have?

Anthem BioSciences has 2282 employees.

What is the current trading status of Anthem BioSciences (ANTHEM)?

As of Nov 06, 2026, Anthem BioSciences (ANTHEM) is trading at a price of 915.00 INR, with a previous close of 913.55 INR. The stock has fluctuated within a day range of 899.10 INR to 922.00 INR, while its 52-week range spans from 579.15 INR to 977.55 INR.

What Is Anthem BioSciences (ANTHEM) Price Target According to Analysts?

The average 12-month price target for Anthem BioSciences is 920.13 INR, with a high estimate of 1050 INR and a low estimate of 850 INR. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +0.56% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.